Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-17.95% $0.660
America/New_York / 20 nov 2023 @ 15:59
FUNDAMENTALS | |
---|---|
MarketCap: | 16.15 mill |
EPS: | -1.930 |
P/E: | -0.342 |
Earnings Date: | Nov 19, 2023 |
SharesOutstanding: | 24.46 mill |
Avg Daily Volume: | 2.39 mill |
RATING 2023-11-20 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.342 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.06x |
Company: PE -0.342 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.603 - 0.717 ( +/- 8.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-17 | Aselage Steve | Sell | 483 741 | Common Stock, $0.0001 par value per share |
2023-11-17 | Dunn John Michael | Sell | 27 380 | Common Stock, $0.0001 par value per share |
2023-11-17 | Joseph Donald | Sell | 14 285 | Common Stock, $0.0001 par value per share |
2023-11-17 | Schelling Chris | Sell | 2 712 529 | Common Stock, $0.0001 par value per share |
2023-11-17 | Palmin Harry S | Sell | 125 000 | Common Stock, $0.0001 par value per share |
INSIDER POWER |
---|
-66.05 |
Last 96 transactions |
Buy: 5 870 002 | Sell: 3 622 222 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.660 (-17.95% ) |
Volume | 0.575 mill |
Avg. Vol. | 2.39 mill |
% of Avg. Vol | 24.07 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.